Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivano Riva

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
The British Journal of Ophthalmology|May 18, 2013
Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertensionAnastasios G P Konstas, Luciano Quaranta, Andreas Katsanos, et al.
Advances in Therapy|June 18, 2016
Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsLuciano Quaranta, Elena Biagioli, Francesca Galli, et al.
Journal of Glaucoma|August 11, 2018
The Glaucoma Italian Pediatric Study (GIPSy): 3-Year ResultsLuciano Quaranta, Elena Biagioli, Ivano Riva, et al.
Hematological Oncology|June 22, 2026
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case SeriesGianluca Cavallaro, Silvia Ferrari, Anna Pollastri, et al.
Ophthalmic Research|December 20, 2011
Risk factors associated with progression in exfoliative glaucoma patientsGábor Holló, Luciano Quaranta, Barbara Cvenkel, et al.
Case Reports in Critical Care|July 19, 2018
Effect of Hemoadsorption for Cytokine Removal in Pneumococcal and Meningococcal SepsisFrancesca Leonardis, Viviana De Angelis, Francesca Frisardi, et al.
Leukemia|June 29, 2021
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, et al.
Leukemia|May 25, 2021
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
The British Journal of Ophthalmology|May 18, 2013
Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertensionAnastasios G P Konstas, Luciano Quaranta, Andreas Katsanos, et al.
Advances in Therapy|June 18, 2016
Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsLuciano Quaranta, Elena Biagioli, Francesca Galli, et al.
Journal of Glaucoma|August 11, 2018
The Glaucoma Italian Pediatric Study (GIPSy): 3-Year ResultsLuciano Quaranta, Elena Biagioli, Ivano Riva, et al.
Hematological Oncology|June 22, 2026
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case SeriesGianluca Cavallaro, Silvia Ferrari, Anna Pollastri, et al.
Ophthalmic Research|December 20, 2011
Risk factors associated with progression in exfoliative glaucoma patientsGábor Holló, Luciano Quaranta, Barbara Cvenkel, et al.
Case Reports in Critical Care|July 19, 2018
Effect of Hemoadsorption for Cytokine Removal in Pneumococcal and Meningococcal SepsisFrancesca Leonardis, Viviana De Angelis, Francesca Frisardi, et al.
Leukemia|June 29, 2021
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, et al.
Leukemia|May 25, 2021
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, et al.
Pageof 8